This project is estimating the lifetime effect of screening on disease outcomes in LS and FCCTX families, stratifying families based on the predicted screening efficiency and defining conditions that will optimize screening across a range of risk levels. We also anticipate that this work will define appropriate guidelines for screening protocols in LS and FCCTX families. The new methods can also be used to assess the impact of screening in other genetically predisposed families, such as those harbouring breast cancer mutations.
Co-Principal Investigators: Dr. Laurent Briollais, Dr. Yun-Hee Choi, Dr. Karen Kopciuk
Funder: Canadian Institutes of Health Research